Jump to a section
- Research scope and peptide identity
- Mechanisms discussed in cited studies
- Study models and experimental designs
- Outcomes measured in the reviewed sources
- Reported study-design and protocol details
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Retatrutide research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This overview summarizes the identity, proposed mechanisms, study models, endpoints, and reported protocol details for retatrutide (LY3437943), a synthetic triple-receptor agonist under clinical development for obesity and related complications. Content is limited to the provided reviewed sources and highlights areas where reporting is incomplete or ongoing.
Research scope and peptide identity
Retatrutide (LY3437943) is described in the reviewed sources as a synthetic triple-receptor agonist that activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors; clinical development has focused on obesity and related cardiometabolic complications. [S1] [S4] [S2]
Clinical investigation has moved from phase 1/2 evaluations into a planned registrational phase 3 program (the TRIUMPH trials) that tests weekly subcutaneous administration across multiple adiposity-related disease states. [S1] [S4]
Mechanisms discussed in cited studies
Reviewed clinical and review sources frame retatrutide's mechanism as simultaneous agonism at GIP, GLP-1, and glucagon receptors; reviews and preclinical summaries attribute downstream effects to reduced food intake, delayed gastric emptying, and combined incretin/glucagon-mediated metabolic actions. [S1] [S2] [S6]
Mechanistic consequences discussed in the reviews include weight lowering and improvements in glycemic and metabolic parameters, while reviews and commentaries also note physiologic effects such as altered gastric motility and potential impacts on lean mass that have been observed with incretin-based therapies. [S2] [S5] [S3]
Study models and experimental designs
A phase 2, randomized, double-blind, placebo-controlled clinical trial enrolled adults with obesity (body-mass index ≥30, or BMI 27–<30 plus a weight-related condition) and randomized them to various once-weekly subcutaneous retatrutide dose cohorts or placebo, with primary efficacy assessment at 24 weeks and continued follow-up to 48 weeks. [S1]
The TRIUMPH program is reported as a multicenter phase 3 development program composed of four randomized, double-blind, placebo-controlled trials using a basket-trial approach to evaluate weekly subcutaneous retatrutide across weight-management and nested protocols for obstructive sleep apnea (OSA) and knee osteoarthritis (OA), enrolling over 5,800 participants. [S4]
Reviews and systematic summaries place retatrutide within the broader incretin and multi-agonist pipeline, noting comparisons to other incretin-based agents and highlighting a mix of preclinical, phase 1, phase 2, and planned phase 3 designs in the literature. [S7] [S2] [S8]
Outcomes measured in the reviewed sources
The phase 2 trial reported percent change in body weight as the primary endpoint at 24 weeks, with additional reported outcomes including percent change at 48 weeks and categorical weight-loss thresholds (≥5%, ≥10%, ≥15%); safety assessments included adverse-event reporting and monitoring of heart rate. [S1]
Clinical and review sources describe metabolic and cardiometabolic outcomes of interest across the program, including glycemic control (HbA1c), liver steatosis and kidney disease markers in review summaries, and disease-specific endpoints planned for phase 3 (apnea–hypopnea index for OSA and WOMAC pain subscale for knee OA). [S2] [S4]
Reviews also draw attention to body-composition outcomes (loss of lean mass observed with incretin-based weight-loss therapies) and functional outcomes related to muscle strength and exercise capacity, noting these as relevant outcomes for adjunctive interventions such as resistance exercise. [S5] [S3]
Reported study-design and protocol details
Phase 2 trial details explicitly reported in the clinical trial excerpt include randomization to multiple fixed-dose cohorts (1 mg; 4 mg with different starting-dose regimens; 8 mg with different starting-dose regimens; and 12 mg with a reported starting-dose regimen), once-weekly subcutaneous administration, enrollment of 338 adults, a primary outcome at 24 weeks and continued treatment/follow-up to 48 weeks, and safety signals that included dose-related gastrointestinal adverse events and dose-dependent increases in heart rate that peaked at 24 weeks. [S1]
TRIUMPH phase 3 program details reported in the design excerpt include four randomized, double-blind, placebo-controlled trials with weekly subcutaneous dosing versus placebo performed in conjunction with healthy diet and physical activity counseling, enrollment of over 5,800 participants, a basket-trial approach permitting independent analysis of weight-management and nested OSA and OA protocols, and primary endpoints defined as percent change in body weight (weight management), change in apnea–hypopnea index (OSA), and change in WOMAC pain subscale (knee OA). [S4]
Several reviews and systematic summaries contextualize these protocols within the broader drug-development pipeline and note that additional data are being collected in ongoing phase 3 trials and that longer-term outcomes, event-based cardiometabolic endpoints, and body-composition preservation strategies are areas of active investigation. [S7] [S2] [S5]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S1] | Phase 2 randomized, double-blind, placebo-controlled trial | Adults with BMI ≥30 or BMI 27– | Participants randomized to subcutaneous retatrutide 1 mg; 4 mg (initial dose 2 mg or 4 mg); 8 mg (initial dose 2 mg or 4 mg); 12 mg (initial dose 2 mg); or placebo | Subcutaneous | Once weekly | 48 weeks | Primary endpoint: percent change in body weight from baseline to 24 weeks; secondary endpoints include percent change at 48 weeks and proportions achieving ≥5%, ≥10%, and ≥15% weight loss; most common adverse events gastrointestinal and dose-related; dose-dependent increases in heart rate peaked at 24 weeks. |
| [S4] | Phase 3 multicenter randomized, double-blind trials (TRIUMPH program; four trials using a basket design) | Adults with obesity; nested cohorts include participants with obstructive sleep apnea and/or knee osteoarthritis; overall enrollment >5,800 participants | not reported in the reviewed source | Subcutaneous | Weekly | not reported in the reviewed source | Basket trial evaluates retatrutide versus placebo plus healthy diet and physical activity; primary endpoints: percent change in body weight (weight management), change in apnea–hypopnea index (OSA), and change in WOMAC pain subscale score (knee OA); independent analyses planned with control of type I error. |
Limitations and research gaps
- Long-term outcomes beyond the reported 48-week phase 2 data are not fully available in the reviewed excerpts; phase 3 results are pending (designs described but not outcome data).
- Mechanistic descriptions in several sources derive from review summaries or preclinical reports rather than consistent, detailed mechanistic data within the clinical trial excerpt provided.
- Some protocol specifics (e.g., exact phase 3 dosing regimens and longer-term safety event rates) were not reported in the reviewed source excerpts.
Documentation checklist
- Confirm receptor-target claims and nomenclature against manufacturer or regulatory labeling (sources report GIP, GLP-1, and glucagon receptor agonism) — see S1, S4.
- Review phase 3 (TRIUMPH) protocol documents for explicit dosing schedules and duration before citing phase 3 regimen details — see S4.
- Assess body-composition and muscle-mass endpoints in trial reports and consider adjunctive resistance-exercise strategies as discussed in reviews — see S5.
- Monitor reported safety signals in source trial data, including gastrointestinal adverse events and heart-rate changes, when summarizing safety — see S1.
Related research supplies
- Temperature-controlled storage cabinets and monitoring logs for investigational product documentation
- Clinical trial labeling supplies and batch/inventory traceability templates
- Electronic case-report forms (eCRF) and data-collection systems for multi-center trials
- Surface and equipment disinfectants compatible with clinical research spaces
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
- [S2] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
- [S3] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
- [S4] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
- [S5] Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care. 2024. PMID: 38687506. DOI: 10.2337/dci23-0100
- [S6] Hong SH, Choi KM. Gut hormones and appetite regulation.. Current opinion in endocrinology, diabetes, and obesity. 2024. PMID: 38511400. DOI: 10.1097/MED.0000000000000859
- [S7] Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L. Emerging pharmacotherapies for obesity: A systematic review.. Pharmacological reviews. 2025. PMID: 39952695. DOI: 10.1124/pharmrev.123.001045
- [S8] Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity?. International journal of obesity (2005). 2025. PMID: 38302593. DOI: 10.1038/s41366-024-01473-y
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.